The global
cell therapy technologies market is projected to reach USD 19.9 billion by
2023 from USD 10.2 billion in 2018, at a CAGR of 14.4% during the forecast
period.
Factors such as
rising government investments for cell-based research, the increasing number of
GMP-certified production facilities, and the large number of oncology-oriented
cell-based therapy clinical trials are driving the growth of this market.
China, India, Japan, Korea, and Brazil are emerging markets
for cell therapy instruments. These markets boast comparatively lenient
standards and government regulations as opposed to developed markets in North
America and the EU, and thus offer significant growth potential for providers.
However, the high cost of cell-based research and the low success rate is
expected to restrain market growth to some extent during the forecast period.
Download PDF
Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21333497
The global cell
therapy technologies market segmentation:
§
cell processing
§
cell preservation
§
distribution And handling
§
cell process monitoring and quality control
Key Market Players
Key players in this cell therapy technologies market include
Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US),
Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL
Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific
(US).
Thermo Fisher was the largest player in the cell therapy
technologies market in 2017. In order to maintain its position in the market
and further expand its product portfolio, the company focuses on the strategies
of product launches, acquisitions, and expansions. Merck holds the second
position in the cell therapy technologies market. The company focuses on
collaborations, agreements, and acquisitions to enhance its market position.
Geographical Detailed
Analysis for the cell therapy instruments market :
The market, by region, is segmented into North America,
Europe, Asia Pacific, and the Rest of the World (RoW). North America is
expected to account for the largest share of this market in 2018. The large
share of this regional segment can primarily be attributed to the high burden
of chronic diseases and increasing R&D activities in pharmaceutical and
biotechnology industries.
The market is dominated by players such as Beckman Coulter,
Inc. (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza
(Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL
Technologies, Inc. (Canada), Terumo BCT, Inc. (US), and Thermo Fisher
Scientific, Inc. (US).
https://www.marketsandmarkets.com/PressReleases/cell-therapy-technologies.asp
No comments:
Post a Comment